안과 임상시험 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global ophthalmic clinical trials market size is expected to reach USD 4.25 Billion in 2034 from USD 2.36 Billion in 2025, growing at a CAGR of 6.75 during 2026-2034.This market is expanding steadily as the prevalence of vision disorders and eye diseases continues increasing worldwide. Ophthalmic clinical trials play a critical role in evaluating the safety and effectiveness of new treatments for conditions such as glaucoma, cataracts, retinal diseases, and dry eye syndrome. Growing investments in pharmaceutical research, biotechnology innovation, and advanced ophthalmic therapies are driving market development. Expanding healthcare infrastructure further supports clinical research activities.

Increasing aging populations and rising incidence of chronic eye diseases are major drivers contributing to market growth. Pharmaceutical companies and research organizations are conducting more clinical studies to develop innovative drugs, biologics, and gene therapies for ophthalmic conditions. Technological advancements in diagnostic imaging, patient monitoring, and digital trial management are improving research efficiency and participant engagement. Supportive regulatory frameworks are also encouraging continued investment in ophthalmic research.

Future prospects remain highly encouraging as precision medicine, regenerative therapies, and artificial intelligence reshape ophthalmic drug development. Decentralized clinical trials, digital health technologies, and advanced imaging solutions will improve study efficiency and patient recruitment. Increasing collaborations among pharmaceutical companies, research institutions, and contract research organizations are expected to accelerate therapeutic innovation. These developments will support sustained long-term growth in the global ophthalmic clinical trials market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Devices (Surgical & Diagnostics Devices, Vision Care Devices)
• Drugs (OTC Drugs, Prescription Drugs)

By Indication

• Macular Degeneration
• Glaucoma
• Dry Eye Disease
• Retinopathy
• Uveitis
• Macular Edema
• Blepharitis
• Cataract
• Optic Neuropathy
• Others

By Phase

• Discovery Phase
• Preclinical Phase
• Clinical Phase

By Sponsor Type

• Pharmaceutical/Biopharmaceutical Companies
• Medical Device Companies
• Others

COMPANIES PROFILED

• Charles River Laboratories International Inc., ClinChoice, Fortrea, ICON Plc, IQVIA, KCR S.A., Laboratory Corporation of America Holdings (Labcorp), Medpace, Novotech, Parexel International, Precision for Medicine Inc., Premier Research, ProRelix Services LLP, ProTrials Research Inc., PSI CRO AG, Syneos Health, Thermo Fisher Scientific Inc. (PPD), Veristat, Vial, Worldwide Clinical Trials Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPHTHALMIC CLINICAL TRIALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Devices (Surgical & Diagnostics Devices, Vision Care Devices) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (OTC Drugs, Prescription Drugs) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPHTHALMIC CLINICAL TRIALS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Macular Degeneration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Dry Eye Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Uveitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Macular Edema Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Blepharitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Cataract Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Optic Neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPHTHALMIC CLINICAL TRIALS MARKET: BY PHASE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Phase
• 6.2. Discovery Phase Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Preclinical Phase Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical Phase Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPHTHALMIC CLINICAL TRIALS MARKET: BY SPONSOR TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Sponsor Type
• 7.2. Pharmaceutical/Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Medical Device Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL OPHTHALMIC CLINICAL TRIALS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Indication
  • 8.2.3 By Phase
  • 8.2.4 By Sponsor Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Indication
  • 8.3.3 By Phase
  • 8.3.4 By Sponsor Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Indication
  • 8.4.3 By Phase
  • 8.4.4 By Sponsor Type
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Indication
  • 8.5.3 By Phase
  • 8.5.4 By Sponsor Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Indication
  • 8.6.3 By Phase
  • 8.6.4 By Sponsor Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL OPHTHALMIC CLINICAL TRIALS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Charles River Laboratories International Inc
  • 10.2.2 ClinChoice
  • 10.2.3 Fortrea
  • 10.2.4 ICON Plc
  • 10.2.5 IQVIA
  • 10.2.6 KCR S.A
  • 10.2.7 Laboratory Corporation Of America Holdings (Labcorp)
  • 10.2.8 Medpace
  • 10.2.9 Novotech
  • 10.2.10 Parexel International
  • 10.2.11 Precision For Medicine Inc
  • 10.2.12 Premier Research
  • 10.2.13 ProRelix Services LLP
  • 10.2.14 ProTrials Research Inc
  • 10.2.15 PSI CRO AG
  • 10.2.16 Syneos Health
  • 10.2.17 Thermo Fisher Scientific Inc. (PPD)
  • 10.2.18 Veristat
  • 10.2.19 Vial
  • 10.2.20 Worldwide Clinical Trials Inc